ALK point mutations resulting in constitutive activation are found in 8–10% of NB [9,10] and gene amplification in a further 2–3% (almost exclusively with MYCN co-amplification) [11], leading to increased ALK activity. The gene discussed is MYCN; the disease is neuroblastoma.